Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Itrade
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(182)
•••
Comment by Chritterson Jul 26, 2021 9:17am
94 Views
Post# 33603574

RE:Itrade

RE:ItradeMine is the exact same as your on Itrade, shows 0.020 Your right. You have to watch this bank they are sneaky crooks, RBC and BMO already changed over of course were the last ones to change, Hate this bank so much


HighSkies2019 wrote: Itrade has my original qty b4 split...but they have market price at 0.02 and this is what is calculated as my price per share balance in my account.... pps close was 0.0225 b4 split ....my account is short 575 as it stands ...hopefully will be adjusted correctly....with ticker code change my account opened back up 30 dollars short. because they upped 3 digit on my pps... I had a snapshot of my account b4 change... they are suppose to be investigating it and still no response ...the first rep tried to tell me no it wasn't changed . .when I said I had a snapshot ...they tried to say maybe surcharge for doing change lol ... anyways heads up on Itrade to make sure calculations is based on 0.0225 not 0.02 on pps b4 split


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities